Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data. (1st July 2022)

• Record Type: Journal Article
• Authors: Paljarvi, Tapio; McPherson, Tess; Luciano, Sierra; Herttua, Kimmo; Fazel, Seena
• Is Part Of: British journal of dermatology. Volume 187:Number 1(2022)
• Page Start: 64
• Page End: 72
• Publication Date: 2022-07-01
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.21049
• Languages: English
• ISSNs: 0007-0963

Abstract

Abstract: Background: Severe neuropsychiatric outcomes have been reported in individuals exposed to isotretinoin, but the evidence is inconclusive and complicated by several methodological limitations. Objectives: To establish and quantify the association between isotretinoin use for acne and 1‐year incident neuropsychiatric adverse outcomes. Methods: A propensity score‐matched cohort study of electronic medical records between the years 2013 and 2019 with patients followed up for 1 year after their index dispensed prescription was conducted. The database included over 12 million patients aged 12–27 years. We analysed data for individuals with acne in this age range with a dispensed prescription for isotretinoin or a control prescription. Outcomes included diagnoses of any incident sleep or mental health disorder, or nonfatal self‐harm within 1 year of the index prescription. Results: We included 30 866 patients prescribed isotretinoin for their acne, 44 748 prescribed oral antibiotics, 108 367 prescribed topical anti‐acne agents and 78 666 patients with acne but without an anti‐acne prescription. After propensity score matching for baseline confounders, the odds ratio (OR) for any incident neuropsychiatric outcomes in patients with acne exposed to isotretinoin was 0·80 [95% confidence interval (CI) 0·74–0·87] compared with those on oral antibiotics; 0·94 (95% CI 0·87–1·02) compared with those using topical anti‐acne medicines; and 1·06 (95% CI 0·97–1·16) compared with those without a prescription for anti‐acne medicines. Patients exposed to isotretinoin experienced significantly more incident physical symptoms than patients in any of the three comparison cohorts. Conclusions: Isotretinoin was not independently associated with excess adverse neuropsychiatric outcomes at the population level. When monitoring potential adverse outcomes during isotretinoin treatment, clinicians should also consider the high mental health burden associated with treatment‐resistant acne and the potential contribution of physical side‐effects of prescribed medication on mental health.